• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Oncolytic Effects of a Novel Influenza A Virus Expressing Interleukin-15 from the NS Reading Frame

tetano

Editor, Senior Moderator
Citation: van Rikxoort M, Michaelis M, Wolschek M, Muster T, Egorov A, et al. (2012) Oncolytic Effects of a Novel Influenza A Virus Expressing Interleukin-15 from the NS Reading Frame. PLoS ONE 7(5): e36506. doi:10.1371/journal.pone.0036506

Marijke van Rikxoort1, Martin Michaelis1?, Markus Wolschek2, Thomas Muster2, Andrej Egorov2, Joachim Seipelt2, Hans Wilhelm Doerr1, Jindrich Cinatl Jr1*

1 Institut f?r Medizinische Virologie, Klinikum der Johann Wolfgang Goethe-Universit?t, Frankfurt am Main, Germany, 2 AVIR Green Hills Biotechnology, Vienna, Austria
Abstract Top

Oncolytic influenza A viruses with deleted NS1 gene (delNS1) replicate selectively in tumour cells with defective interferon response and/or activated Ras/Raf/MEK/ERK signalling pathway. To develop a delNS1 virus with specific immunostimulatory properties, we used an optimised technology to insert the interleukin-15 (IL-15) coding sequence into the viral NS gene segment (delNS1-IL-15). DelNS1 and delNS1-IL-15 exerted similar oncolytic effects. Both viruses replicated and caused caspase-dependent apoptosis in interferon-defective melanoma cells. Virus replication was required for their oncolytic activity. Cisplatin enhanced the oncolytic activity of delNS1 viruses. The cytotoxic drug increased delNS1 replication and delNS1-induced caspase-dependent apoptosis. Interference with MEK/ERK signalling by RNAi-mediated depletion or the MEK inhibitor U0126 did not affect the oncolytic effects of the delNS1 viruses. In oncolysis sensitive melanoma cells, delNS1-IL-15 (but not delNS1) infection resulted in the production of IL-15 levels ranging from 70 to 1140 pg/mL in the cell culture supernatants. The supernatants of delNS1-IL-15-infected (but not of delNS1-infected) melanoma cells induced primary human natural killer cell-mediated lysis of non-infected tumour cells. In conclusion, we constructed a novel oncolytic influenza virus that combines the oncolytic activity of delNS1 viruses with immunostimulatory properties through production of functional IL-15. Moreover, we showed that the oncolytic activity of delNS1 viruses can be enhanced in combination with cytotoxic anti-cancer drugs.


http://www.plosone.org/article/info...osone/PLoSONE+(PLoS+ONE+Alerts:+New+Articles)
 
Back
Top Bottom